Avaleht › Müeloom › Alabama › Birmingham
Müeloom kliinilised uuringud linnas Birmingham, AL
18 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Birmingham ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
VärbamineFaas 1/2
- University of Alabama At Birmingham Hospital, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- Alabama Oncology, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 2
- University of Alabama Birmingham, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1/2
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
VärbamineFaas 2
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
VärbamineFaas 3
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 2
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1/2
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
VärbamineFaas 1/2
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
VärbamineFaas 2
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
VärbamineFaas 1
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
VärbamineFaas 2
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
Värbamine
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
VärbamineVaatlusuuring
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1/2
- UAB Comprehensive Cancer Center, Birmingham
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Birmingham
- Vähk (kõik liigid)30 uuringut
- Rinnavähk24 uuringut
- Rasvumine23 uuringut
- Munasarjavähk23 uuringut
- Mitteväikerakuline kopsuvähk22 uuringut
- Äge müeloidne leukeemia21 uuringut
- KOKH17 uuringut
- Kardiovaskulaarsed haigused17 uuringut
- Ülekaalulisus16 uuringut
- Endomeetriumivähk16 uuringut
- 2. tüüpi diabeet16 uuringut
- Tsüstiline fibroos16 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.